Skip to main navigation Skip to search Skip to main content

Early administration of the GIP receptor antagonist (Pro(3))GIP counters development of hyperglycaemia, glucose intolerance and insulin resistance in genetic obesity

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
Pages (from-to)0171
JournalDiabetologia
Volume49
Issue numberSuppl.
Publication statusPublished (in print/issue) - Sept 2006

Bibliographical note

42nd Annual Meeting of the European-Association-for-the-Study-of-Diabetes (EASD), Copenhagen,
DENMARK, SEP 14-17, 2006

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Cite this